3 research outputs found
Load-balanced route optimization method for accident aboard a ship
An emergency evacuation system is a system that helps people in the space to evacuate safely and quickly from emergencies in the event of an emergency. Such systems are essential as the size of vessels becomes larger and more complex. However, current emergency evacuation systems play only a limited role. For example, evacuation route guidance through placement of real human resources or evacuation route such as direction of emergency exit point which is pointed in one direction only in one place. Relying on human subjective judgment in a dangerous situation can be quite dangerous, and emergency lights and escape routes that always point in the same direction are not able to deal flexibly with risk factors and can expose the public to danger. Furthermore, due to the nature of the ship structure, the initial response is important as the rescue time is delayed rather than the land accident.
Therefore, emergency evacuation systems should be more intelligent in increasingly complicated and larger structures, and should be able to quickly identify information on the surrounding situation and suggest an optimal evacuation route. In particular, it is not possible to exclude the possibility that dangerous elements may spread or become dangerous areas in the route where evacuees are passing.
Therefore, there is a need for a system that predicts and responds to the near future through sufficient modeling of risk factors. Among various risk factors, risk factors such as fire, smoke, and isolation can be sufficiently collected by using sensors or image processing devices. However, in the case of bottlenecks, it is essential to model the density of the population at the current node, the direction in which people at that location will evacuate, and whether the path of the selected path will accommodate the incoming population. Therefore, we propose a bottleneck modeling method and load balancing based on disaster situation in this paper. The proposed performance is verified by computer simulation.Chapter 1. Introduction 1
1.1 Research background 1
1.2 Research Trends 1
1.3 Research Necessity 3
1.4 Research Summary 3
Chapter 2. Related Theory and Research 4
2.1 Searching Algorithm 4
2.1.1 State Space and Search 4
2.1.2 Blind Search 5
2.1.3 Heuristic Search 7
2.1.4 Algorithm 8
2.1.4.1 Operation Process 9
2.2 Searching System 12
2.2.1 Feeling Factor 12
2.2.2 Risk Predicted Value 14
2.2.3 Evacuation System for accident situation 16
Chapter 3. Proposed Scheme 17
3.1 Graph Search for inside of ship 17
3.2 Modeling of bottleneck 18
3.3 Proposed Route Optimization Algorithm 22
Chapter 4. Simulation and Analysis 23
4.1 Bottleneck occurrence probability 23
4.1.1 Experiment environment and result 23
4.2 Weighted distance according to proposed scheme 25
4.3 Evacuation time according to proposed scheme 27
Chapter 5. Conclusiond 28
References 29Maste
μ΄κΈ° νν¨μ¨λ³μμ ν₯ν 보νλκ²° λ°μμ μμΈ‘μΈμλ€: μμμ , λνλ―Ό μ΄λ°μ²΄ μμ λ° λμ²μμ‘ μ§νλ€
νμλ
Όλ¬Έ(μμ¬)--μμΈλνκ΅ λνμ :μκ³Όλν μνκ³Ό,2020. 2. μ λ²μ.Objective The aim of this study was to determine whether dopamine transporter (DAT) imaging and cerebrospinal fluid (CSF) parameters can be used as a predictor of freezing of gait (FOG) in patients with early Parkinsons disease (PD). In addition, we further investigated the predictive value of clinical, DAT imaging and CSF markers for the development of FOG both separately and in combination.
Methods This cohort study using the Parkinsons Progression Markers Initiative data included a total of 393 early PD patients without FOG. Demographic and clinical data, DAT imaging results, and CSF marker levels including Ξ²-amyloid 1-42 (AΞ²42), Ξ±-synuclein, total tau, phosphorylated tau181, and the calculated ratio of AΞ²42 to total tau were collected at baseline. The FOG data up to 4 years of follow-up were included. The development of FOG was defined to be present if the score was 1 or greater either for the Movement Disorder Society Unified Parkinsons Disease Rating Scale (MDS-UPDRS) item 2.13 or item 3.11 at any point during the follow-up period. Cox regression models were conducted to identify the factors predictive of FOG. Based on these results, we constructed a predictive model for the development of FOG.
Results During a median follow-up of 4.0 years (mean 3.0 years), 136 patients developed FOG, and its cumulative incidence was 17, 21, 28, and 37% at 1-, 2-, 3- and 4-year follow-up, respectively. Among DAT imaging and CSF markers, caudate DAT uptake (hazard ratio [HR] 0.581; 95% confidence interval [CI] 0.408β0.827; p=0.003) and CSF AΞ²42 (HR 0.997; 95% CI 0.996β0.999; p=0.009) were predictive of FOG. Postural instability gait difficulty (PIGD) score (HR 1.494; 95% CI 1.282β1.741; p<0.001) and, to a lesser extent, male sex (HR 1.512; 95% CI 1.007β2.271; p=0.046), MDS-UPDRS motor score (HR 1.022; 95% CI 1.000β1.045; p=0.046), and Montreal Cognitive Assessment score (HR 0.927; 95% CI 0.860β0.995; p=0.035) were also related to the development of FOG. The combined model integrating the PIGD score, caudate DAT uptake, and CSF AΞ²42 achieved a better prediction accuracy (area under the curve 0.755; 95% CI 0.700β0.810) than any factor alone.
Conclusions This study found striatal DAT uptake and CSF AΞ²42 as predictors of FOG in patients with early PD. Furthermore, FOG development within 4 years after PD diagnosis can be predicted with acceptable accuracy using our risk model.μλ‘ λνλ―Όμ΄λ°μ²΄ μμ λ° λμ²μμ‘ μ§νλ€μ΄ μ΄κΈ° νν¨μ¨λ³ νμμμ 보νλκ²°μ μμΈ‘μΈμμΌ μ μλμ§λ₯Ό μμλ³΄κ³ μμμ§νμμ μ‘°ν©μ ν΅ν΄ ν₯ν 보νλκ²° λ°μμ μ΄λ μ λ μμΈ‘ν μ μλμ§λ₯Ό λΆμνμλ€.
λ°©λ² Parkinson's progression markers initiative (PPMI) μ°κ΅¬λ μ΄κΈ° νν¨μ¨λ³ νμμμ ν₯ν μ¦μλ€μ μ§νμ μμΈ‘νλ λ°μ΄μ€λ§μ»€λ₯Ό λ°κ²¬νκ³ κ²μ¦νκΈ° μν΄ κ³ μλ κ΅μ λ€κΈ°κ΄ μ½νΈνΈ μ°κ΅¬μ΄λ€. λ³Έ μ°κ΅¬λ PPMI λ°μ΄ν°λ₯Ό μ΄μ©νμκ³ 4λ
κΉμ§ κ²½κ³Όκ΄μ°°ν λ°μ΄ν°λ₯Ό ν¬ν¨νμλ€. μ΄κΈ° νν¨μ¨λ³ νμλ€ μ€ λ³΄νλκ²°μ΄ μλ 393λͺ
μ΄ μ°κ΅¬μ ν¬ν¨λμλ€. 보νλκ²°μ λ°μμ Movement Disorders Society Unified Parkinsons Disease Rating Scale (MDS-UPDRS) νλͺ© 2.13γλλ νλͺ© 3.11μ λ΅μ΄ 1μ μ΄μμΈ κ²½μ°λ‘ μ μνμλ€. μ½μ€ νκ·λͺ¨λΈμ μννμ¬ λ³΄νλκ²°μ μμΈ‘ μΈμλ₯Ό νμΈνμκ³ μ΄λ¬ν κ²°κ³Όλ₯Ό λ°νμΌλ‘ μμΈ‘ λͺ¨λΈμ κ°λ°νμλ€.
κ²°κ³Ό νκ· 3.0λ
(μ€μκ° 4.0λ
)κ°μ μΆμ κ΄μ°° λμ 136λͺ
μ νμλ€μμ 보νλκ²°μ΄ λ°μνμκ³ λ³΄νλκ²°μ λμ λ°μλ₯ μ 1, 2, 3, 4λ
κ²½κ³Όκ΄μ°°μμ κ°κ° 17, 21, 28 λ° 37%μλ€. λνλ―Όμ΄λ°μ²΄ μμ λ° λμ²μμ‘ μ§νλ€ μ€ λ―Έμν΅ λνλ―Ό μ΄λ°μ²΄ μμ·¨ κ°μ (μνλΉ 0.581; 95% μ λ’°κ΅¬κ° 0.408-0.827; p=0.003) λ° λ² νμλ°λ‘μ΄λ 1-42 (μνλΉ 0.997; 95% μ λ’°κ΅¬κ° 0.996-0.999; p=0.009)κ° λ³΄νλκ²°μ λ°μκ³Ό κ΄λ ¨μ΄ μμλ€. μ΄μΈμ 보νμ₯μ -μμΈλΆμ μ μ (p<0.001), λ¨μ± (p=0.046), MDS-UPDRS μ΄λ μ μ (p=0.046) λ° λͺ¬νΈλ¦¬μ¬ μΈμ§νκ° μ μ (p=0.035)κ° λ³΄νλκ²°μ μμΈ‘νμλ€. 보νμ₯μ -μμΈλΆμ μ μ, λ―Έμν΅ λνλ―Ό μ΄λ°μ²΄ μμ·¨ κ°μ λ° λμ²μμ‘ λ² νμλ°λ‘μ΄λ 1-42λ₯Ό μ‘°ν©ν μμΈ‘λͺ¨λΈμ area under curveλ 0.755 (95% μ λ’°κ΅¬κ° 0.700β0.810)λ‘ μΈ‘μ λμλ€.
κ²°λ‘ μ΄ μ°κ΅¬λ μ΄κΈ° νν¨μ¨λ³ νμμμ μ 쑰체μ λνλ―Όκ²°ν λ° λμ²μμ‘ λ² νμλ°λ‘μ΄λ 1-42κ° ν₯ν 보νλκ²° λ°μμ μμΈ‘μΈμμΈ κ²μ νμΈνμλ€. λν μ°λ¦¬μ μνλͺ¨λΈμ νν¨μ¨λ³ μ§λ¨ ν 4 λ
μ΄λ΄μ 보νλκ²° λ°μμ μμ© κ°λ₯ν μ λμ μ νλλ‘ μμΈ‘νμλ€.Introduction 1
Materials and Methods 3
Results 7
Discussion 10
Conclusion 13
References 14
Tables and Figures 18
Acknowledgement 23
Abstract (in Korean) 24Maste
AIMP2-DX2 μ μ μμ 2λ² μμ μ ν© λ³νμ΄ κΈμ± 골μμ± λ°±νλ³ λ° κΈ°ν μμ’ μμ κ°μ§λ μμμ μλ―Έ
νμλ
Όλ¬Έ (μμ¬)-- μμΈλνκ΅ λνμ : μνκ³Ό, 2017. 2. μ€μ±μ.Aminoacyl tRNA synthetase complex-interacting multifunctional protein 2 (AIMP2) is a potent tumor suppressor. An exon-2 depleted splicing variant ofAIMP2 (AIMP2-DX2) is responsible for tumorigenesis by compromising the tumor suppressive activity of AIMP2. This study aimed to investigate the role ofAIMP2-DX2 over diverse cancers using whole transcriptome data in The Cancer Genome Atlas (TCGA), and International Cancer Genome Consortium (ICGC) database. A total of 753 samples were analyzed for the presence of AIMP2-DX2 and its prognostic role in various cancers. AIMP2-DX2 was universally expressed to varying degrees, with a prognostic implication in several cancers. In acute myemyeloid leukemia (AML), AIMP2-DX2/AIMP2 ratio was strongly correlated with major cancer signaling pathways, and had a tendency toward exhibiting poor prognosis (Log rank P=0.16). We validated the prognostic implication of AIMP2-DX2 using AML patient samples. For 51 AML patients, overall survival (OS) and progression-free survival (PFS) of AIMP2-DX2 positive patients were significantly
inferior to that of AIMP2-DX2 negative patients (for OS: hazard ratio [HR] 2.4795% confidence interval [CI] 1.14β5.34P=0.022for PFS: HR 2.5995% CI
1.32β5.11P=0.006). Collectively, AIMP2-DX2 may be a novel biomarker and a potential therapeutic target for AML.I. Introduction 1
II. Materials and Methods 3
III. Results 9
IV. Discussion 24
V. Conclusions 28
VI. References 29
Supplementary materials 34
Supplementary Figures 34
Supplementary Tables 51
κ΅λ¬Έ μ΄λ‘ 54Maste